Lymphoma is a cancer type where uncontrollable growth of lymphocytes (WBCs) initiating from lymph glands or lymphatic tissue or other parts of the lymphatic system, including bone marrow, tonsils, testicles, spleen and lymph nodes.
This excess growth of lymphocytes often accumulates in lymph nodes. Though this accumulation can occur in any body part, commonly affected parts are armpits, neck and groin and rarely in lungs or bones.
The non-inheritable and non-contageous disease is one of the common types of cancer but can be treated with patients’ life expectancy remaining quite large post-treatment.
Genomic alterations in lymphocytes cause damage to the lifecycle of these cells, boosting the cell division rate or affecting the death period. However, causes for such gene changes are yet to be determined.
Phases of Lymphoma cancer- -Single group of lymph nodes (above or below diaphragm) -Multiple group of lymph nodes are affected(above or below diaphragm) -Expands to both sides of diaphragm -Expands to bone marrow or other body parts
Types of Lymphoma Cancer- Though two types of Lymphoma are defined, it is often difficult to determine the exact sub-type of Lymphoma.
* Hodgkin Lymphoma In Hodgkin Lymphoma, the cancer cells called Reed-Sternberg (RS) cells, have a characteristic appearance under microscope.
Further subtypes- Nodular Sclerosis: Lymph nodes contain Reed-Sternberg cells mixed with normal white blood cells
Mixed Cellularity: Lymph nodes contain several Reed-Sternberg cells in addition to several other cell types
Lymphocyte-rich: Lymph nodes contain several normal- appearing lymphocytes and classic Reed-Sternberg cells
Lymphocyte-depleted: Lymph nodes contain large volume of Reed-Sternberg cells and few normal lymphocytes
Nodular lymphocyte-predominant Hodgkin lymphoma: Lymph nodes contain several abnormal B cells and Reed-Sternberg cells are rarely observed
* Non-Hodgkin Lymphoma Unlike Hodgkin Lymphoma, the cancer cells called Reed-Sternberg cells are absent in this subtype of Lymphoma
High grade NHL
* B-cell NHL Lymphoma Diffuse large B-cell (DLBCL): Abnormal growth of large B-Cells in different body parts
Intravascular B-Cell: Occurs due to explosion of lymphocytes within tiny vessels with no involvement of the organ parenchyma
Primary mediastinal large B-cell: Large neoplastic cells with B-cell derivation are observed
Burkitt: Most aggressive form, classified as endemic (African) type, sporadic type and HIV related
Primary central nervous system: DLBCL sub-type affecting the brain and or spinal cord
* T-cell NHL Lymphoma Peripheral T-cell (PTCL NOS): Abnormal growth of T-cells which are not specified under any category
Anaplastic large cell: It can occur in the skin or in other organs throughout the body
Angioimmunoblastic T-cell: the body’s immune system does not recognize, and consequently destroys, its own cells and tissues
Enteropathy-associated: occurs in the intestines and is mostly associated with celiac disease
Nasal-type NK/T-cell: Natural killer cells often affecting the nasal area, trachea, gastrointestinal tract, or skin
Hepatosplenic T-cell: Abnormal growth of T-cells in liver or spleen
Lymphoblastic: The T-cells outgrow in number when a bone marrow cell develops alterations in its gene code
Low Grade NHL Follicular: B-cells are affected; Enlargement of the lymph nodes in the neck, underarm, stomach, groin
Small lymphocytic: B-lymphocytes, with enlarged nodes affecting neck, armpit or groin
Lympho-plasmacytic: Enlarged cells make varying volumes of immunoglobin M protein in the blood, making it thick (condition referred to as Waldenstrom macroglobulinemi)
MALT Lymphoma (Gastric and Non-gastric): mucosa-associated lymphoid tissue (MALT) starts outside lymph nodes, usually in lymphatic tissue in the mucous membranes or tissues lining organs
Splenic marginal zone: The NHL sub-type affects spleen, bone marrow and blood
Nodal marginal zone: Mostly occurs in lymph nodes and rarely in spleen or bone marrow Mantle Cell Lymphoma clinical trials report from VPA Research provides comprehensive analysis and trends in global Mantle Cell Lymphoma disease clinical trials. The research work analyzes the evolution of Mantle Cell Lymphoma clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Mantle Cell Lymphoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Mantle Cell Lymphoma clinical trials.
Major drugs under development in Mantle Cell Lymphoma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.
Scope of the Report- - Number of Mantle Cell Lymphoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas - Trial information by Phase and Subjects recruited - Trial information by status, type, sponsor type - Drugs used for treatment of Mantle Cell Lymphoma - Both observational and interventional trials analyzed - Success rates of trials are analyzed - Trends in enrollment over the past ten years identified - Leading sponsors of Mantle Cell Lymphoma clinical trials worldwide are listed
Reasons to Buy- - Track competition and design competitive advantages - Identify right partners to associate with for further research - Evaluate potential opportunities available in further clinical trials of the disease - Formulate business development strategies through success rates of clinical trials - Identify quick markets for recruiting subjects based on trials count by each market
Our reports have been used by over 10K customers, including:
“Richter’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Richter’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
“Soft Tissue Sarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period. Market growth is largely driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis...
Sezary Syndrome - Global Clinical Trials Review, H1, 2021 Summary clinical trial report, “Sezary Syndrome - Global Clinical Trials Review, H1, 2021" provides an overview of Sezary Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Sezary Syndrome....
The global radiotherapy market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Additionally,...
Global Flow Cytometry in Oncology Market to Reach $5.25 Billion by 2031 Market Report Coverage - Flow Cytometry in Oncology Market Segmentation • Product Type – Assays and Kits, Instruments, Reagents and Consumables, and Software • Technology – Cell-Based and Bead-Based • Type of...
The global neoantigens market is expected to reach US$ 10,54,783.54 thousand by 2028 from US$ 2,71,428.57 thousand in 2020. It is estimated to grow at a CAGR of 18.49% during 2020-2028. Cancer has emerged as a leading cause of death worldwide.According to the World Health Organization (WHO), cancer was the first leading cause of death...
397 pages •
By Roots Analysis Private Ltd.
• Mar 2021
INTRODUCTION The inherent heterogeneity of cancer cells and the immunosuppressive properties of the tumor microenvironment make it difficult to design viable and effective therapeutics against oncological disorders. However, targeted cell-based immunotherapies have demonstrated significant potential in treating patients...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.